<?xml version="1.0" encoding="UTF-8"?>
<p>In elderly populations, these CMV-driven immune changes have been associated with reduced vaccine responses and an increased risk of mortality (
 <xref rid="bib71" ref-type="bibr">Wikby et al., 1994</xref>, 
 <xref rid="bib72" ref-type="bibr">2002</xref>; 
 <xref rid="bib13" ref-type="bibr">Ferguson et al., 1995</xref>; 
 <xref rid="bib59" ref-type="bibr">Trzonkowski et al., 2003</xref>; 
 <xref rid="bib38" ref-type="bibr">Moro-Garc√≠a et al., 2012</xref>; 
 <xref rid="bib10" ref-type="bibr">Derhovanessian et al., 2013</xref>, 
 <xref rid="bib11" ref-type="bibr">2014</xref>). However, although marked changes in immune phenotype and significant proportions of CMV-specific T cells are also observed in healthy younger seropositive adults and children (
 <xref rid="bib60" ref-type="bibr">Turner et al., 2014</xref>; 
 <xref rid="bib5" ref-type="bibr">Brodin et al., 2015</xref>; 
 <xref rid="bib62" ref-type="bibr">van den Heuvel et al., 2016</xref>), the impact on responses to vaccination or infection is less clear, and most studies have been conducted in populations within developed countries (
 <xref rid="bib52" ref-type="bibr">Sidorchuk et al., 2004</xref>; 
 <xref rid="bib22" ref-type="bibr">Holder et al., 2010</xref>; 
 <xref rid="bib49" ref-type="bibr">Saghafian-Hedengren et al., 2013</xref>; 
 <xref rid="bib60" ref-type="bibr">Turner et al., 2014</xref>; 
 <xref rid="bib16" ref-type="bibr">Furman et al., 2015</xref>; 
 <xref rid="bib61" ref-type="bibr">van den Berg et al., 2018</xref>).
</p>
